Free Trial

SciSparc (SPRC) Competitors

SciSparc logo
$3.82 -0.11 (-2.80%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$3.78 -0.03 (-0.92%)
As of 10/17/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SPRC vs. TNFA, VIVS, KZIA, ALZN, PLRZ, PMCB, SNGX, SNOA, QLGN, and NLSP

Should you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include TNF Pharmaceuticals (TNFA), VivoSim Labs (VIVS), Novogen (KZIA), Alzamend Neuro (ALZN), Polyrizon (PLRZ), Nuvilex (PMCB), Soligenix (SNGX), Sonoma Pharmaceuticals (SNOA), Qualigen Therapeutics (QLGN), and NLS Pharmaceutics (NLSP). These companies are all part of the "pharmaceutical products" industry.

SciSparc vs. Its Competitors

TNF Pharmaceuticals (NASDAQ:TNFA) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

9.6% of TNF Pharmaceuticals shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 0.5% of TNF Pharmaceuticals shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

SciSparc's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
TNF PharmaceuticalsN/A -69.21% -33.98%
SciSparc N/A N/A N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TNF Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
SciSparc
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

SciSparc has higher revenue and earnings than TNF Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TNF PharmaceuticalsN/AN/A-$23.36M-$231.00-0.02
SciSparc$1.31M1.55-$6.28MN/AN/A

TNF Pharmaceuticals has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, SciSparc has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

In the previous week, SciSparc had 7 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 7 mentions for SciSparc and 0 mentions for TNF Pharmaceuticals. SciSparc's average media sentiment score of 1.00 beat TNF Pharmaceuticals' score of 0.00 indicating that SciSparc is being referred to more favorably in the news media.

Company Overall Sentiment
TNF Pharmaceuticals Neutral
SciSparc Positive

Summary

SciSparc beats TNF Pharmaceuticals on 8 of the 9 factors compared between the two stocks.

Get SciSparc News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRC vs. The Competition

MetricSciSparcMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.04M$3.02B$6.20B$10.53B
Dividend YieldN/A54.20%5.70%4.82%
P/E RatioN/A23.3185.7027.13
Price / Sales1.55597.25580.78177.79
Price / CashN/A169.4137.1060.81
Price / Book0.215.3212.236.52
Net Income-$6.28M$33.06M$3.33B$276.93M
7 Day Performance-4.74%2.29%1.17%1.93%
1 Month Performance-19.92%7.35%6.85%2.19%
1 Year Performance-20.63%-5.13%58.93%34.62%

SciSparc Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPRC
SciSparc
0.5129 of 5 stars
$3.82
-2.8%
N/A-20.6%$2.04M$1.31M0.004Positive News
Gap Down
TNFA
TNF Pharmaceuticals
0.0683 of 5 stars
$3.89
+5.7%
N/A-97.5%$7.19MN/A-0.026
VIVS
VivoSim Labs
1.2206 of 5 stars
$2.74
-7.4%
N/AN/A$7.12M$140K-0.2720Short Interest ↓
KZIA
Novogen
3.8912 of 5 stars
$6.98
+2.5%
$16.50
+136.4%
-72.1%$7.05M$1.51M0.0012Short Interest ↓
Gap Up
ALZN
Alzamend Neuro
2.4527 of 5 stars
$2.24
+1.8%
$42.00
+1,775.0%
-85.3%$7.03MN/A0.004News Coverage
Analyst Forecast
Short Interest ↑
PLRZ
Polyrizon
N/A$1.17
-0.8%
N/AN/A$7.01MN/A0.00N/APositive News
Short Interest ↓
Gap Down
PMCB
Nuvilex
0.0854 of 5 stars
$1.03
+3.0%
N/A-43.3%$7.00MN/A-1.914Short Interest ↑
High Trading Volume
SNGX
Soligenix
2.4602 of 5 stars
$1.63
-5.2%
$6.00
+268.1%
-57.4%$6.99M$120K-0.4320
SNOA
Sonoma Pharmaceuticals
1.0875 of 5 stars
$4.07
flat
N/A+21.2%$6.68M$14.29M-1.65180News Coverage
QLGN
Qualigen Therapeutics
N/A$3.81
-5.0%
N/A-56.5%$6.48M$4.98M0.0050Short Interest ↑
Gap Down
NLSP
NLS Pharmaceutics
N/A$1.78
+0.6%
N/A-69.1%$6.41MN/A0.006News Coverage
Analyst Forecast
Short Interest ↑
Gap Down

Related Companies and Tools


This page (NASDAQ:SPRC) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners